scholarly journals Lung cancer mortality risk among breast cancer patients treated with anti-estrogens

Cancer ◽  
2011 ◽  
Vol 117 (6) ◽  
pp. 1288-1295 ◽  
Author(s):  
Christine Bouchardy ◽  
Simone Benhamou ◽  
Robin Schaffar ◽  
Helena M. Verkooijen ◽  
Gerald Fioretta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
Lung Cancer Mortality ◽  
Breast Cancer Patients ◽  
Cancer Mortality Risk

BMI, long-term changes in BMI, and risk of cancer mortality in a large cohort study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1502-1502
Author(s):  
Niloofar Taghizadeh ◽  
Judith M. Vonk ◽  
H. Marike Boezen
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lung Cancer ◽  
Cohort Study ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
Lung Cancer Mortality ◽  
Prostate Cancer Mortality ◽  
Risk Of Mortality ◽  
Cancer Mortality Risk

1502 Background: There are indications of an association between Body Mass Index (BMI) and risk of different cancer types. There is dispute whether this association differs between males and females. Methods: We studied the association of BMI at the first survey with risk of mortality from the most common types of cancer (lung, colorectal, breast and prostate cancer) in a large general population-based cohort study (Vlagtwedde-Vlaardingen, 1965-1990) with follow-up on mortality status until 2009. Additionally, we assessed this association based on tertiles of the annual change in BMI (defined as the difference between BMI at last survey and first survey divided by the time between last and first survey). We used 3 categories of BMI (< 25 kg/m2, 25-30 kg/m2, and ≥ 30 kg/m2) and changes in BMI (< 0.02 kg/m2/yr, 0.02-0.2 kg/m2/yr, and > 0.2 kg/m2/yr) in the analyses. The multivariate Cox regression model was adjusted for age, smoking, gender. Analyses were additionally stratified by gender and smoking. Results: Among all 8645 subjects, 1194 died due to cancer (lung cancer: 275; colorectal cancer: 134; breast cancer: 117; prostate cancer: 83). Mortality from all types of cancer was significantly increased in subjects with BMI > 30 kg/m2 (HR (95 % CI)) = 1.22 (1.00-1.48)), especially in females (1.38 (1.06-1.81)) and in never smokers (1.39 (1.02-1.90)). Prostate cancer mortality was significantly increased in males with BMI 25-30 kg/m2 (2.04 (1.90-3.83)) and > 30 kg/m2 (2.61 (1.02-6.67)). This association between prostate cancer mortality and BMI was higher in smokers. Lung cancer mortality risk was decreased in subjects with BMI 25-30 kg/m2 (0.71 (0.54-0.93)) and > 30 kg/m2 (0.82 (0.50-1.32)), especially in males, in smokers, and in smoking males. There were no significant associations between BMI and colorectal or breast cancer mortality nor between change in BMI and mortality from all analyzed types of cancer. Conclusions: We show that an increase in BMI is associated with an increased risk of mortality from all types of cancer in females and with an increased mortality risk from prostate cancer in males but with a decreased lung cancer mortality risk, especially in males. More research is needed into the biological mechanisms that link BMI to cancer.

scholarly journals Portable stove use is associated with lower lung cancer mortality risk in lifetime smoky coal users

2008 ◽  
Vol 99 (11) ◽  
pp. 1934-1939 ◽  
Author(s):  
H D Hosgood ◽  
R Chapman ◽  
M Shen ◽  
A Blair ◽  
E Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
Lung Cancer Mortality ◽  
Lower Lung ◽  
Smoky Coal ◽  
Cancer Mortality Risk

scholarly journals Changes in Spirometry Indices and Lung Cancer Mortality Risk Estimation in Concrete Workers Exposed io Crystalline Silica

2020 ◽  
Vol 21 (9) ◽  
pp. 2811-2817
Author(s):  
Somayeh Rahimi Moghadam ◽  
Narges Khanjani ◽  
Mahmoud Mohamadyan ◽  
Mojtaba Emkani ◽  
Saeed Yari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
Risk Estimation ◽  
Lung Cancer Mortality ◽  
Crystalline Silica ◽  
Cancer Mortality Risk

scholarly journals On the Application of Combine Soft Set with Near Set in Predicting the Lung Cancer Mortality Risk

2021 ◽  
Vol 6 (2) ◽  
pp. 332-343
Author(s):  
Amr Hassan Abedhaliem ◽  
Mohamed Ali Atiea ◽  
Mohamed Elsayed Wahed ◽  
Mohamed Saleh Metwally
Keyword(s):  
Lung Cancer ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
Lung Cancer Mortality ◽  
Soft Set ◽  
Cancer Mortality Risk

Variation in the efficacy of low-dose computed tomographic lung screening based on risk of lung cancer mortality in the National Lung Screening Trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1523-1523
Author(s):  
Hormuzd A. Katki ◽  
Stephanie A Kovalchik ◽  
Martin Tammemagi ◽  
Christine D. Berg ◽  
Neil Caporaso ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mortality Risk ◽  
Cancer Mortality ◽  
False Positive ◽  
Lung Cancer Mortality ◽  
Lung Cancer Death ◽  
National Lung Screening Trial ◽  
Lung Screening ◽  
Cancer Mortality Risk ◽  
Screening Trial

1523 Background: Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the National Lung Screening Trial (NLST). The efficacy of LDCT screening could be improved by targeting smokers at highest risk of lung cancer death, provided that the efficacy of LDCT screening increases with lung cancer mortality risk. Methods: We evaluated the efficacy of LDCT screening as compared to chest radiography in the NLST across groups defined by participants’ 5-year risk of lung cancer mortality at randomization, which was estimated using a validated prediction model. Across quintiles of 5-year lung cancer mortality risk [Q1: 0.15%-0.55%, Q2: 0.56%-0.84%, Q3: 0.85%-1.24%, Q4: 1.24%-2.0%, Q5: >2.0%], we estimated the number of participants with false positive screens, the number of prevented lung cancer deaths, and their ratio. Results: The number of prevented lung cancer deaths due to LDCT screening increased in tandem with lung cancer mortality risk (Q1=0.2, Q2=3.5, Q3=5.1, Q4=11.0, Q5=12.0 per 10,000 person-years; P-trend=0.01). The number of participants with false positive screens per lung cancer death prevented, a measure of screening efficiency, significantly decreased with increasing risk (Q1=1,648, Q2=181, Q3=147, Q4=64, Q5=65, P-trend<0.001). The 60% of participants at highest 5-year lung cancer mortality risk (0.85% or greater) accounted for 88% of LDCT-preventable lung cancer deaths and included only 64% of participants with a false positive screen. The 20% of participants at lowest lung cancer mortality risk (0.15%-0.55%) accounted for only 1% of LDCT-preventable lung cancer deaths. Conclusions: In the NLST, LDCT screening prevented the most lung cancer mortality among those at highest lung cancer mortality risk and prevented almost no mortality among those at lowest risk, providing empirical support for risk-based targeting of smokers to improve the efficacy of LDCT screening.

Sign in / Sign up

Export Citation Format

Share Document